Public Defence: Ida Storhaug Frøysnes - Surgical Oncology Ida Storhaug Frøysnes at Institute of Clinical Medicine will be defending the thesis “Novel therapeutic approaches in peritoneal metastasis from colorectal cancer” for the degree of PhD.

Photo: Beate Willumsen

Trial Lecture - time and place

See Trial Lecture.

Adjudication committee

  • First  opponent: Professor Olivier Glehen, Lyon Sud Charles Mérieux Medical Faculty, University Lyon 1, France
  • Second opponent: Professor Karen-Lise Garm Spindler, Department of Clinical Medicine, Aarhus University, Denmark
  • Third member and chair of the adjudication committee: Professor Øyvind Sverre Bruland, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo

Chair of the Defence

Professor II Gunnar Sæter, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo

Principal Supervisor

Professor II Kjersti Flatmark, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo


Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can offer long-term survival in patients with resectable peritoneal metastasis (PM) from colorectal cancer (CRC), a condition with otherwise dismal prognosis.

In the first part of her PhD work, Ida Storhaug Frøysnes focused on the current treatment for this patient group, investigating outcome and associated prognostic factors following CRS-HIPEC in Norway. There was acceptable morbidity and no 100-day mortality, the 5-year overall survival (OS) and disease-free survival (DFS) were 36% and 14%, respectively, with a median follow-up of 45 months. The only factor associated with OS in multivariable analysis was tumor burden, expressed by the peritoneal cancer index.

Although CRS-HIPEC may offer long-term survival to patients with PM-CRC, most patients experience disease recurrence, and novel therapeutic options are needed. MOC31PE immunotoxin was in-house developed to rapidly kill cells expressing the tumor-associated epithelial cell adhesion molecule (EpCAM), which is highly expressed in CRC. In the second part of Frøysnes’ work, MOC31PE immunotoxin was given intraperitoneally for the first time in the phase I/II ImmunoPeCa-trial. The aim was to evaluate safety and toxicity (primary endpoint), pharmacokinetics, neutralizing antibody response, OS and DFS (secondary endpoints). Frøysnes and co-authors reported no dose limiting toxicity, the maximum tolerated dose was not reached, and there was negligible systemic drug absorption. Drug concentrations in peritoneal fluid samples were in the cytotoxic range, and MOC31PE recovered from the peritoneal cavity retained its cytotoxic activity in cell based assays. Three-year OS and DFS were 78% and 33%, respectively. The promising long-term outcome combined with low systemic absorbance, high drug concentration and cytotoxic activity in peritoneal fluid support further investigations of clinical efficacy.                                          

Additional information

Contact the research support staff.

Published Feb. 8, 2019 11:06 AM - Last modified Feb. 8, 2019 12:28 PM